Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Type 1 Diabetes Mellitus
Interventions
DEVICE

Sansum Closed-Loop Artificial Pancreas

The Sansum Closed-loop Artificial Pancreas Device is the infrastructure that allows communication between the insulin pump, the CGM, the zone-MPC, and the HMS.

DEVICE

Insulin infusion pump

The insulin pump, which has received 510k clearance (K080639), delivers insulin subcutaneously through an infusion set.

DEVICE

Continuous Glucose Monitor

The CGM, which is an approved device (P050012), measures interstitial glucose.

DEVICE

zone-Model Predictive Control algorithm

The zone-MPC predicts future glucose values, based on CGM data, to regulate blood glucose level by increasing, decreasing, or stopping insulin infusion via an insulin infusion pump.

DEVICE

Safety Health Monitoring System

The HMS predicts future glucose values, based on CGM data, to warn the Sansum Closed-loop Artificial Pancreas Device of values below 70 mg/dL.

Trial Locations (1)

93105

Sansum Diabetes Research Institute, Santa Barbara

All Listed Sponsors
collaborator

University of California, Santa Barbara

OTHER

lead

Sansum Diabetes Research Institute

OTHER

NCT01472406 - Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS) | Biotech Hunter | Biotech Hunter